CK Hutchison Pauses AS Watson Dual Listing
The parent company has deferred the planned Hong Kong and London listing of its health and beauty retailer, with a timeline that could extend to 2027.
Updated on Nov. 12, 2026 in Business Strategy

CK Hutchison has paused the planned spin-off and dual listing of AS Watson in Hong Kong and London. The listing had previously been shelved during the Covid-19 period, and the group has been targeting a valuation of around US$30 billion.
Why it matters
The deferral leaves the retailer's expansion funding and the parent company's capital plans unresolved, as the listing depends on regulatory steps still outstanding. Market sentiment and weaker mainland consumption trends are cited as pressures on the timing.
The targeted valuation is about US$30 billion, with roughly US$2 billion sought through primary issuance and Temasek holding about 25 per cent of AS Watson. Mainland China health and beauty stores fell 11 per cent, while cybersecurity approval remains pending.
The players
CK Hutchison
A Hong Kong-based conglomerate that owns AS Watson and oversees a diverse portfolio of retail, ports, and telecommunications businesses across multiple countries.
AS Watson
A global health and beauty retailer with a large store network across Asia and Europe, marking its 185th anniversary this year.
Temasek
A Singapore-based state investment company that holds about 25 per cent of AS Watson and is one of its major shareholders.
The details
CK Hutchison had appointed UBS and Goldman Sachs at the start of the year to lead the IPO process. The company said the deferral reflects market conditions and ongoing regulatory procedures, and AS Watson plans to add about 1,000 stores this year with HK$3.8 billion in planned investment.
Timeline
During the Covid-19 period, the original AS Watson spin-off was shelved.
At the start of 2026, UBS and Goldman Sachs were appointed to lead the IPO process.
Mid-2026 was the original target for completing the dual listing.
The 30 June 2026 interim report disclosed the retail store count and mainland closures.
The listing timeline could extend to 2027.
Business Strategy Landscape
The deferral follows the listing having been shelved during the Covid-19 period, and the revised timeline now points toward 2027 as regulatory approvals remain pending. The pattern suggests the parent company is facing repeated delays in monetizing its largest retail asset.
For shoppers, the immediate effect is limited because AS Watson's store expansion and HK$3.8 billion in planned upgrades continue regardless of the listing timing. The delay mainly affects investors waiting for access to the retailer's shares.
The takeaway
A delayed listing does not stop operations, but it signals that capital-raising plans for large retail assets can slip when regulatory approvals and market conditions move against them. Readers tracking the sector can watch for the cybersecurity approval as the next concrete marker.
What happens next
The listing timeline depends on cybersecurity approval from China's authorities, and the company has indicated the process could extend to 2027.
Further reading
For broader context on how companies plan listings and expansions, see the Business Strategy section.



